STOCK TITAN

[6-K] Virax Biolabs Group Limited Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Atomico Advisors IV, Ltd. and its affiliated funds have filed a Schedule 13G disclosing a passive ownership position in Hinge Health, Inc. (HNGE) following the company’s 23 May 2025 IPO.

  • Aggregate beneficial ownership: 6,713,063 Class B shares, convertible 1-for-1 into Class A.
  • Economic stake equals 8.3 % of the 80,597,784 total shares outstanding post-IPO.
  • All voting and dispositive power is reported as shared; no sole power.
  • Class B shares carry 15 votes per share, giving Atomico considerably greater voting influence than its economic interest implies; this higher voting weight is not reflected in the 8.3 % figure because percentages are shown on an as-converted basis.
  • The filing is made under Rule 13d-1(c)/(d), indicating a passive investment intent with no activist agenda disclosed.

The disclosure confirms that a prominent venture investor has retained a meaningful stake through the IPO. While it does not change financial outlook, the dual-class structure heightens governance concentration, a consideration for shareholders assessing control dynamics.

Atomico Advisors IV, Ltd. e i suoi fondi affiliati hanno presentato un modulo Schedule 13G, rivelando una posizione di proprietà passiva in Hinge Health, Inc. (HNGE) a seguito dell’IPO del 23 maggio 2025.

  • Proprietà beneficiaria complessiva: 6.713.063 azioni di Classe B, convertibili 1 a 1 in azioni di Classe A.
  • La quota economica corrisponde a 8,3% delle 80.597.784 azioni totali in circolazione dopo l’IPO.
  • Tutti i poteri di voto e dispositivi sono riportati come condivisi; nessun potere esclusivo.
  • Le azioni di Classe B attribuiscono 15 voti per azione, conferendo ad Atomico un’influenza di voto significativamente superiore rispetto alla sua quota economica; questo peso di voto maggiore non è riflesso nella percentuale dell’8,3% poiché le percentuali sono indicate su base convertita.
  • La dichiarazione è stata effettuata ai sensi della Regola 13d-1(c)/(d), indicando un intento di investimento passivo senza alcuna agenda attivista dichiarata.

La comunicazione conferma che un investitore di rilievo nel venture capital ha mantenuto una partecipazione significativa attraverso l’IPO. Pur non modificando le prospettive finanziarie, la struttura a doppia classe aumenta la concentrazione del controllo, un aspetto da considerare per gli azionisti che valutano le dinamiche di governance.

Atomico Advisors IV, Ltd. y sus fondos afiliados han presentado un Schedule 13G revelando una posición de propiedad pasiva en Hinge Health, Inc. (HNGE) tras la OPI del 23 de mayo de 2025.

  • Propiedad beneficiaria agregada: 6,713,063 acciones Clase B, convertibles 1 a 1 en Clase A.
  • La participación económica equivale al 8.3% de las 80,597,784 acciones totales en circulación después de la OPI.
  • Todo el poder de voto y disposición se reporta como compartido; sin poder exclusivo.
  • Las acciones Clase B otorgan 15 votos por acción, lo que da a Atomico una influencia de voto considerablemente mayor que su interés económico; este mayor peso de voto no se refleja en el 8.3% porque los porcentajes se muestran en base convertida.
  • La presentación se realiza bajo la Regla 13d-1(c)/(d), indicando una intención de inversión pasiva sin agenda activista divulgada.

La divulgación confirma que un inversor destacado de capital de riesgo ha mantenido una participación significativa a través de la OPI. Aunque no cambia las perspectivas financieras, la estructura de doble clase aumenta la concentración de gobernanza, un aspecto a considerar para los accionistas que evalúan las dinámicas de control.

Atomico Advisors IV, Ltd. 및 그 계열 펀드들은 2025년 5월 23일 회사의 IPO 이후 Hinge Health, Inc. (HNGE)에 대한 수동적 소유 지분을 공개하는 Schedule 13G를 제출했습니다.

  • 총 실질 소유 지분: 6,713,063 클래스 B 주식, 1대1로 클래스 A로 전환 가능.
  • 경제적 지분은 IPO 후 총 80,597,784주 중 8.3%에 해당.
  • 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 단독 권한은 없음.
  • 클래스 B 주식은 주당 15표의 의결권을 가지며, 이는 Atomico가 경제적 지분보다 훨씬 큰 의결 영향력을 가진다는 의미입니다; 이 높은 의결권 가중치는 8.3% 수치에 반영되지 않았으며, 비율은 전환 기준으로 표시됩니다.
  • 이 제출은 Rule 13d-1(c)/(d)에 따라 이루어졌으며, 수동적 투자 의도를 나타내며 활동적 개입 의도는 공개되지 않았습니다.

이 공개는 주요 벤처 투자자가 IPO를 통해 의미 있는 지분을 유지하고 있음을 확인시켜 줍니다. 재무 전망에는 변화가 없지만, 이중 클래스 구조는 지배구조 집중도를 높여 주주들이 지배 구조 역학을 평가할 때 고려해야 할 사항입니다.

Atomico Advisors IV, Ltd. et ses fonds affiliés ont déposé un Schedule 13G révélant une position de propriété passive dans Hinge Health, Inc. (HNGE) suite à l’introduction en bourse du 23 mai 2025.

  • Participation bénéficiaire globale : 6 713 063 actions de Classe B, convertibles 1 pour 1 en actions de Classe A.
  • La part économique équivaut à 8,3 % des 80 597 784 actions totales en circulation après l’IPO.
  • Tout pouvoir de vote et de disposition est déclaré comme partagé ; aucun pouvoir exclusif.
  • Les actions de Classe B donnent 15 voix par action, conférant à Atomico une influence de vote bien supérieure à son intérêt économique ; ce poids de vote plus élevé n’est pas reflété dans le chiffre de 8,3 % car les pourcentages sont présentés sur une base convertie.
  • Le dépôt est effectué conformément à la règle 13d-1(c)/(d), indiquant une intention d’investissement passive sans agenda activiste divulgué.

Cette divulgation confirme qu’un investisseur en capital-risque de premier plan a conservé une participation significative lors de l’IPO. Bien que cela ne modifie pas les perspectives financières, la structure à double catégorie d’actions accentue la concentration de la gouvernance, un élément à considérer pour les actionnaires évaluant les dynamiques de contrôle.

Atomico Advisors IV, Ltd. und ihre verbundenen Fonds haben eine Schedule 13G eingereicht, die eine passive Beteiligungsposition an Hinge Health, Inc. (HNGE) nach dem Börsengang am 23. Mai 2025 offenlegt.

  • Gesamtwirtschaftliches Eigentum: 6.713.063 Class-B-Aktien, 1:1 in Class-A-Aktien wandelbar.
  • Der wirtschaftliche Anteil entspricht 8,3 % der insgesamt 80.597.784 nach dem IPO ausstehenden Aktien.
  • Alle Stimm- und Verfügungsrechte werden als geteilt angegeben; keine alleinige Kontrolle.
  • Class-B-Aktien haben 15 Stimmen pro Aktie, was Atomico eine deutlich größere Stimmkraft als den wirtschaftlichen Anteil verleiht; dieses höhere Stimmgewicht spiegelt sich nicht in der 8,3-%-Zahl wider, da die Prozentsätze auf umgerechneter Basis angegeben sind.
  • Die Einreichung erfolgt gemäß Regel 13d-1(c)/(d) und weist auf eine passive Investitionsabsicht ohne aktivistische Agenda hin.

Die Offenlegung bestätigt, dass ein bedeutender Risikokapitalinvestor eine wesentliche Beteiligung durch den Börsengang behalten hat. Obwohl sich dies nicht auf die finanzielle Prognose auswirkt, erhöht die Dual-Class-Struktur die Konzentration der Unternehmensführung, was für Aktionäre bei der Bewertung der Kontrollverhältnisse zu berücksichtigen ist.

Positive
  • Atomico Advisors IV disclosed a sizable 6.7 M-share, 8.3 % stake, signaling continued confidence in Hinge Health post-IPO
  • Presence of a well-known venture firm may be viewed favorably by other investors and partners
Negative
  • Dual-class structure grants 15x voting power, concentrating governance and potentially diluting minority influence
  • No financial metrics, strategic initiatives, or additional capital commitments were provided

Insights

TL;DR: Atomico holds 8.3 % of HNGE, boosting voting power via 15-vote Class B shares; information is noteworthy but not thesis-changing.

The 13G shows Atomico kept 6.7 M shares after Hinge Health’s IPO, translating to an 8.3 % economic stake. Because these are Class B shares with 15 votes each, Atomico’s effective influence could exceed 30 % of total voting rights, reinforcing the founders’ and early investors’ control. The filing is passive, so no immediate strategic shift is implied. Investors may view continued backing from a top-tier VC as a confidence signal, but absent financial data or transaction terms, the event is modestly informative rather than valuation-moving.

Atomico Advisors IV, Ltd. e i suoi fondi affiliati hanno presentato un modulo Schedule 13G, rivelando una posizione di proprietà passiva in Hinge Health, Inc. (HNGE) a seguito dell’IPO del 23 maggio 2025.

  • Proprietà beneficiaria complessiva: 6.713.063 azioni di Classe B, convertibili 1 a 1 in azioni di Classe A.
  • La quota economica corrisponde a 8,3% delle 80.597.784 azioni totali in circolazione dopo l’IPO.
  • Tutti i poteri di voto e dispositivi sono riportati come condivisi; nessun potere esclusivo.
  • Le azioni di Classe B attribuiscono 15 voti per azione, conferendo ad Atomico un’influenza di voto significativamente superiore rispetto alla sua quota economica; questo peso di voto maggiore non è riflesso nella percentuale dell’8,3% poiché le percentuali sono indicate su base convertita.
  • La dichiarazione è stata effettuata ai sensi della Regola 13d-1(c)/(d), indicando un intento di investimento passivo senza alcuna agenda attivista dichiarata.

La comunicazione conferma che un investitore di rilievo nel venture capital ha mantenuto una partecipazione significativa attraverso l’IPO. Pur non modificando le prospettive finanziarie, la struttura a doppia classe aumenta la concentrazione del controllo, un aspetto da considerare per gli azionisti che valutano le dinamiche di governance.

Atomico Advisors IV, Ltd. y sus fondos afiliados han presentado un Schedule 13G revelando una posición de propiedad pasiva en Hinge Health, Inc. (HNGE) tras la OPI del 23 de mayo de 2025.

  • Propiedad beneficiaria agregada: 6,713,063 acciones Clase B, convertibles 1 a 1 en Clase A.
  • La participación económica equivale al 8.3% de las 80,597,784 acciones totales en circulación después de la OPI.
  • Todo el poder de voto y disposición se reporta como compartido; sin poder exclusivo.
  • Las acciones Clase B otorgan 15 votos por acción, lo que da a Atomico una influencia de voto considerablemente mayor que su interés económico; este mayor peso de voto no se refleja en el 8.3% porque los porcentajes se muestran en base convertida.
  • La presentación se realiza bajo la Regla 13d-1(c)/(d), indicando una intención de inversión pasiva sin agenda activista divulgada.

La divulgación confirma que un inversor destacado de capital de riesgo ha mantenido una participación significativa a través de la OPI. Aunque no cambia las perspectivas financieras, la estructura de doble clase aumenta la concentración de gobernanza, un aspecto a considerar para los accionistas que evalúan las dinámicas de control.

Atomico Advisors IV, Ltd. 및 그 계열 펀드들은 2025년 5월 23일 회사의 IPO 이후 Hinge Health, Inc. (HNGE)에 대한 수동적 소유 지분을 공개하는 Schedule 13G를 제출했습니다.

  • 총 실질 소유 지분: 6,713,063 클래스 B 주식, 1대1로 클래스 A로 전환 가능.
  • 경제적 지분은 IPO 후 총 80,597,784주 중 8.3%에 해당.
  • 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 단독 권한은 없음.
  • 클래스 B 주식은 주당 15표의 의결권을 가지며, 이는 Atomico가 경제적 지분보다 훨씬 큰 의결 영향력을 가진다는 의미입니다; 이 높은 의결권 가중치는 8.3% 수치에 반영되지 않았으며, 비율은 전환 기준으로 표시됩니다.
  • 이 제출은 Rule 13d-1(c)/(d)에 따라 이루어졌으며, 수동적 투자 의도를 나타내며 활동적 개입 의도는 공개되지 않았습니다.

이 공개는 주요 벤처 투자자가 IPO를 통해 의미 있는 지분을 유지하고 있음을 확인시켜 줍니다. 재무 전망에는 변화가 없지만, 이중 클래스 구조는 지배구조 집중도를 높여 주주들이 지배 구조 역학을 평가할 때 고려해야 할 사항입니다.

Atomico Advisors IV, Ltd. et ses fonds affiliés ont déposé un Schedule 13G révélant une position de propriété passive dans Hinge Health, Inc. (HNGE) suite à l’introduction en bourse du 23 mai 2025.

  • Participation bénéficiaire globale : 6 713 063 actions de Classe B, convertibles 1 pour 1 en actions de Classe A.
  • La part économique équivaut à 8,3 % des 80 597 784 actions totales en circulation après l’IPO.
  • Tout pouvoir de vote et de disposition est déclaré comme partagé ; aucun pouvoir exclusif.
  • Les actions de Classe B donnent 15 voix par action, conférant à Atomico une influence de vote bien supérieure à son intérêt économique ; ce poids de vote plus élevé n’est pas reflété dans le chiffre de 8,3 % car les pourcentages sont présentés sur une base convertie.
  • Le dépôt est effectué conformément à la règle 13d-1(c)/(d), indiquant une intention d’investissement passive sans agenda activiste divulgué.

Cette divulgation confirme qu’un investisseur en capital-risque de premier plan a conservé une participation significative lors de l’IPO. Bien que cela ne modifie pas les perspectives financières, la structure à double catégorie d’actions accentue la concentration de la gouvernance, un élément à considérer pour les actionnaires évaluant les dynamiques de contrôle.

Atomico Advisors IV, Ltd. und ihre verbundenen Fonds haben eine Schedule 13G eingereicht, die eine passive Beteiligungsposition an Hinge Health, Inc. (HNGE) nach dem Börsengang am 23. Mai 2025 offenlegt.

  • Gesamtwirtschaftliches Eigentum: 6.713.063 Class-B-Aktien, 1:1 in Class-A-Aktien wandelbar.
  • Der wirtschaftliche Anteil entspricht 8,3 % der insgesamt 80.597.784 nach dem IPO ausstehenden Aktien.
  • Alle Stimm- und Verfügungsrechte werden als geteilt angegeben; keine alleinige Kontrolle.
  • Class-B-Aktien haben 15 Stimmen pro Aktie, was Atomico eine deutlich größere Stimmkraft als den wirtschaftlichen Anteil verleiht; dieses höhere Stimmgewicht spiegelt sich nicht in der 8,3-%-Zahl wider, da die Prozentsätze auf umgerechneter Basis angegeben sind.
  • Die Einreichung erfolgt gemäß Regel 13d-1(c)/(d) und weist auf eine passive Investitionsabsicht ohne aktivistische Agenda hin.

Die Offenlegung bestätigt, dass ein bedeutender Risikokapitalinvestor eine wesentliche Beteiligung durch den Börsengang behalten hat. Obwohl sich dies nicht auf die finanzielle Prognose auswirkt, erhöht die Dual-Class-Struktur die Konzentration der Unternehmensführung, was für Aktionäre bei der Bewertung der Kontrollverhältnisse zu berücksichtigen ist.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41440

Virax Biolabs Group Limited

(Registrant’s Name)

BioCity Glasgow

Bo'Ness Road Newhouse

Lanarkshire, ML1 SUH

United Kingdom

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

 

 

When used in this Form 6-K, unless otherwise indicated, the terms “the Company,” “Virax,” “we,” “us” and “our” refer to Virax Biolabs Group Limited. and its subsidiaries.

 

Information Contained in this Form 6-K Report

 

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On July 28, 2025, Mr. Yair Erez resigned as an independent director of the Board (the “Board”) of Virax Biolabs Group Limited (the “Company”), to focus on other professional endeavors, effective immediately. The resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.

On July 28, 2025, the Board appointed Dr. Iain Miller to fill in the vacancy on the Board, resulting from Mr. Erez’s resignation, effective immediately. The Board also appointed Dr. Miller to serve on each of the Compensation Committee, Nominating and Corporate Governance Committee, and Audit Committee of the Board.

Dr. Miller has over 30 years of diverse executive-level experience, with a focus on in-vitro diagnostic and precision medicine sectors, including development of AI-powered clinical decision support solutions and companion diagnostic products. Dr. Miller currently serves as a non-executive board director of Pictura Bio, which he joined in 2022. Previously, from 2016 to 2018, Dr. Miller served as a part time CEO and board member for SAW Diagnostics. From 2019 to June 2025, he served as CEO and board member for Presymptom Health. From 2013 to 2019, he served as CEO of Healthcare Strategies Group. Prior to these roles, Dr. Miller served in various roles in other biotechnology focused companies. Dr. Miller obtained an MBA with distinction from Edinburgh Business School, Scotland in 2000, a Ph.D. BioEngeineerinig from the University of Strathclyde, and a B.S, Physics/Engineering Combined Honors from the University of Glasgow. Dr. Miller is a Member of the Association of British Healthcare Industries and British In


Vitro Diagnostics Association. We believe Dr. Miller's extensive experience qualifies him to serve as one of our independent directors.

Dr. Iain Miller was not appointed pursuant to any arrangement or understanding between him and any other person and has no family relationships with any of the executive officers or directors of the Company.

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

VIRAX BIOLABS GROUP LIMITED

Date:

July 30, 2025

By:

/s/ James Foster

James Foster, Chief Executive Officer

 

 


FAQ

How many HNGE shares does Atomico own according to the Schedule 13G?

Atomico beneficially owns 6,713,063 Class B shares, convertible into an equal number of Class A shares.

What percentage of Hinge Health does Atomico’s stake represent?

The filing reports an 8.3 % economic ownership based on shares outstanding immediately after the IPO.

Do Atomico’s Class B shares carry additional voting power?

Yes. Each Class B share has 15 votes versus one vote for Class A, giving Atomico outsized voting influence.

Is the investment deemed passive or activist?

The Schedule 13G is filed under Rule 13d-1, indicating a passive investment intent with no activist plans disclosed.

When did the event triggering this filing occur?

The report references the date of event as 23 May 2025, coinciding with Hinge Health’s IPO.
Virax Biolabs Group Ltd

NASDAQ:VRAX

VRAX Rankings

VRAX Latest News

VRAX Latest SEC Filings

VRAX Stock Data

3.84M
3.90M
6.63%
6.72%
4.67%
Biotechnology
Healthcare
Link
United Kingdom
Lanarkshire